文献速递妇科产科

子宫癌肉瘤:当代临床总结、分子更新与未来研究方向

Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
PubMed 文献 · Gynecol Oncol · 2020-11-09

子宫癌肉瘤(UCS)是一种双相侵袭性高级别子宫内膜癌,近年发病率逐渐上升,2000至2016年年变化百分比为1.7%(95%CI 1.2-2.2),在子宫内膜癌中占比超过5%。多模式治疗为主,但生存结局仍差,中位生存不足两年,5年总生存率数十年无改善(1975年31.9%至2012年33.8%)。卡铂/紫杉醇辅助化疗较异环磷酰胺/紫杉醇改善无进展生存,尤其III-IV期。上皮-间质转化在肉瘤去分化中起关键作用。

要点

  • UCS发病率逐年上升,2000-2016年年变化百分比1.7%,占子宫内膜癌比例超5%。
  • 肉瘤成分>50%与生存下降相关;卡铂/紫杉醇辅助化疗改善PFS,尤其III-IV期。
  • 复发/转移性UCS一线治疗中位缓解率37.5%,中位PFS 5.9个月,后续治疗更差。

核心结论

  • UCS发病率上升且生存结局数十年无显著改善,中位生存不足两年,5年总生存率从1975年31.9%至2012年33.8%。
  • 卡铂/紫杉醇辅助化疗较异环磷酰胺/紫杉醇改善无进展生存,尤其III-IV期(GOG-261试验)。
  • 上皮-间质转化在肉瘤去分化中起关键作用,异源性肉瘤较同源性肉瘤具有更高的EMT特征。

研究设计与样本

  • 当代综述,总结UCS的临床与分子更新,并讨论EMT作为潜在治疗靶点。
  • 引用26项临床试验评估复发/转移性UCS的治疗效果。
  • 提及GOG-261试验比较卡铂/紫杉醇与异环磷酰胺/紫杉醇辅助化疗。

主要发现

  • UCS发病率年变化百分比1.7%(95%CI 1.2-2.2),在子宫内膜癌中占比超过5%。
  • 肉瘤成分>50%与生存下降相关;近年发生分期偏移,淋巴结转移增加而远处转移减少。
  • 复发/转移性UCS一线治疗后中位缓解率37.5%,中位PFS 5.9个月;后续治疗中位缓解率5.5%,中位PFS 1.8个月。
  • 下一代测序显示UCS肿瘤呈浆液性样,常见体细胞突变为TP53、PIK3CA、FBXW7、PTEN和ARID1A。

关键数值与推荐

  • UCS在子宫内膜癌中占比超过5%(近年)。
  • 肉瘤成分>50%的子宫肿瘤与生存下降相关。
  • 5年总生存率1975年31.9%,2012年33.8%。
  • 复发/转移性UCS一线治疗中位缓解率37.5%,中位PFS 5.9个月;后续治疗中位缓解率5.5%,中位PFS 1.8个月。

临床怎么用

  • 多模式治疗是UCS的主要治疗方式,淋巴结切除术、化疗和近距离放疗在过去数十年中使用增加。
  • 卡铂/紫杉醇辅助化疗可考虑用于UCS,尤其III-IV期,较异环磷酰胺/紫杉醇改善无进展生存。
  • 肉瘤成分>50%提示生存下降,可用于风险分层。
  • EMT可能是UCS的潜在治疗靶点,异源性肉瘤EMT特征更高。

局限性

  • 为综述性总结,未报告原始研究的具体样本量、P值等细节。
  • 生存结局数据来自历史比较,未提供近期随机对照试验的长期生存结果。
  • EMT作为治疗靶点仍处于讨论阶段,尚无临床验证数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Uterine carcinosarcoma (UCS) is a biphasic aggressive high-grade endometrial cancer in which the sarcoma element has de-differentiated from the carcinoma element. UCS is considered a rare tumor, but its incidence has gradually increased in recent years (annual percent change from 2000 to 2016 1.7%, 95% confidence interval 1.2-2.2) as has the proportion of UCS among endometrial cancer, exceeding 5% in recent years. UCS typically affects the elderly, but in recent decades patients became younger. Notably, a stage-shift has occurred in recent years with increasing nodal metastasis and decreasing distant metastasis. The concept of sarcoma dominance may be new in UCS, and a sarcomatous element >50% of the uterine tumor is associated with decreased survival. Multimodal treatment is the mainstay of UCS. Lymphadenectomy, chemotherapy, and brachytherapy have increased in the past few decades, but survival outcomes remain dismal: the median survival is less than two years, and the 5-year overall survival rate has not changed in decades (31.9% in 1975 to 33.8% in 2012). Carboplatin/paclitaxel adjuvant chemotherapy improves progression-free survival compared with ifosfamide/paclitaxel, particularly in stages III-IV disease (GOG-261 trial). Twenty-six clinical trials previously examined therapeutic effectiveness in recurrent/metastatic UCS. The median response rate and progression-free survival were 37.5% and 5.9 months, respectively, after first-line therapy, but after later therapies, the outcomes were far worse (5.5% and 1.8 months, respectively). One significant discovery was that epithelial-mesenchymal transition (EMT) plays a pivotal role in the pathogenesis of sarcomatous dedifferentiation in UCS and that heterologous sarcoma is associated with a higher EMT signature compared with homologous sarcoma. Furthermore, next-generation sequencing has revealed that UCS tumors are serous-like and that common somatic mutations include those in TP53, PIK3CA, FBXW7, PTEN, and ARID1A. This contemporary review highlights recent clinical and molecular updates in UCS. A possible therapeutic target of EMT in UCS is also discussed.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matsuzaki S, Klar M, Matsuzaki S, et al. Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2020. PMID: 33183764. doi:10.1016/j.ygyno.2020.10.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。